<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>COGNITIVE IMPAIRMENT IN LONG-COVID SYNDROME (BRAIN FOG): NEUROINFLAMMATORY MARKERS AND LONG-TERM PROGNOSES</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Azamat</mods:namePart><mods:namePart type="family">Khabibullayev</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Dilshodaxon</mods:namePart><mods:namePart type="family">Khakikatbekova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Background: Long-COVID syndrome, or the post-acute sequelae of SARS-CoV-2 infection, has emerged as a significant public health challenge, with "brain fog" being one of its most debilitating neurological manifestations. This cognitive dysfunction encompasses deficits in attention, executive function, and memory, severely impacting the quality of life. This article explores the underlying mechanisms of cognitive impairment in Long-COVID patients, focusing on the pivotal role of neuroinflammatory markers and evaluating long-term clinical prognoses.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-05-30</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>SIR Publishers</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>